Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes pharmaceutical products to treat patients with unmet medical needs. It commercializes multiple biotechnology products and also receives royalties from companies that are... more

ImClone Systems Incorporated (ImClone) is a biopharmaceutical company that develops a portfolio of targeted biologic treatments designed to address the medical needs of patients with cancer. The Company focuses on two systems for treating cancer: growth factor blockers and angiogenesis... more

Amgen Inc. is a biotechnology company that discovers, develops, manufactures and markets human therapeutics-based on advances in cellular and molecular biology. The Company operates in human therapeutics. It markets human therapeutic products in the areas of supportive cancer care,... more

Exelixis, Inc. is a biotechnology company engaged in the development of differentiated pharmaceutical products for the treatment of cancer and other serious diseases. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease... more

YM BioSciences Inc. (YM BioSciences) is engaged in the licensing and commercialization of drug products and technologies from original research. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor... more

Adherex Technologies Inc. a biopharmaceutical company focused on cancer therapeutics with preclinical and clinical product candidates. The Company has three product candidates in the clinical stage of development. Eniluracil is a dihydropyrimidine dehydrogenase (DPD) inhibitor that was... more

Lorus Therapeutics Inc. (Lorus) is a life sciences company focused on the discovery, research and development of anticancer therapies. The Company has worked to establish a diverse anticancer product pipeline, with products in various stages of development ranging from pre-clinical to an... more

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship... more

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that harness the immune system to fight cancer. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy... more

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets proprietary and licensed oncology products through its in-house specialty sales force: Quadramet® (a skeletal targeting therapeutic radiopharmaceutical for the relief of... more

SuperGen, Inc. is a pharmaceutical company dedicated primarily to the discovery, development and commercialization of therapies to treat patients with cancer. The Company acquires products that were developed by other companies and applies additional developmental effort to expand sales... more

Pro-Pharmaceuticals, Inc. is a development stage company engaged in the discovery, development, and commercialization of first-in-class, targeted therapeutic compounds for advanced treatment of cancer, liver, microbial and inflammatory diseases. The Company focuses on the development of a... more

Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. The Company's discovery engines integrate cell cycle biology... more

Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its compounds bavituximab and Cotara... more

ImmunoGen, Inc. is focused on the development of antibody-based anticancer therapeutics. The Company’s Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to cancer cells. The antibody component enables a TAP compound to bind... more

Avalon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Its lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase II clinical development.... more

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes... more

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s lead products, which are in clinical-stage testing, consist of ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase; ARQ 501, an... more

Genta Incorporated (Genta) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases. Genta’s research portfolio consists... more

NeoRx is a cancer therapeutics development company dedicated to the development and commercialization of oncology products that impact the lives of individuals afflicted with cancer and metastases. The Company currently is focusing its development efforts on picoplatin, a... more

CancerVax Corporation is a leading edge biotechnology company focused on the discovery, development and commercialization of products for the treatment and control of cancer. CancerVax Corporation is firmly committed to building value by developing innovative products that extend life... more

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent development programs in the areas of infectious disease and... more

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90... more

Abraxis BioScience, Inc., formerly New Abraxis, Inc., is an integrated biotechnology companies, with a marketed product (Abraxane), global ownership of its technology platform and pipeline, dedicated nanoparticle manufacturing capabilities for worldwide supply integrated with seasoned... more

BiPar Sciences is a privately held biopharmaceutical company committed to creating a world-class drug development and commercialization organization that addresses significant unmet medical needs in oncology. Our lead product candidate is BSI-201, which is now in a Phase 1a trial as a... more

Oncolytics Biotech Inc. is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is in the research and... more

SGX Pharmaceuticals (formerly Structural GenomiX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. SGX's oncology pipeline includes drug candidates from its enabling, proprietary FASTÔ drug discovery platform, such... more

Progen Pharmaceuticals Limited (Progen) is an Australia-based company. During the fiscal year ended June 30, 2008 (fiscal 2008), the principal activities of the Company were discovery, research and development of biopharmaceutical therapeutics for the treatment of human diseases, and the... more

Vion Pharmaceuticals, Inc. is a development stage pharmaceutical company engaged in the development of products for the treatment of cancer. Its portfolio of product candidates consists of two small molecules, Cloretazine (VNP40101M) and Triapine anticancer agents in clinical development,... more

Procyon Biopharma (Procyon) is a biotechnology company actively engaged in the development of innovative therapeutics in the fields of cancer and HIV/AIDS. The Company leverages its strengths in clinical research and development, bringing products through early- to mid-stage clinical... more

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing small molecule drugs. The Company develops oral anticancer therapies... more

At Corvas International Inc., we are dedicated to developing breakthrough medicines with the potential to profoundly improve the lives of millions of people living with cardiovascular disease and cancer. Our commitment is to bring to the market a new generation of biotherapeutics with... more

Advanced Viral Research Corp. (Advanced Viral) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. The Company's products may be useful for the treatment... more

Gemin X is developing small molecules that target specialized pathways for cancer, including key regulators in the genesis and progression of cancer.

At Semafore we are dedicated to discovering and developing the next generation of novel cancer therapeutics. Semafore currently employs over 20 people and is headquartered in Indianapolis, Indiana --home of the famous Indy 500 and leading a growing life sciences environment in the State.... more

Helix BioPharma Corp. is a Canada-based biopharmaceutical company developing products for the treatment of cancer and prevention of cancer. Its revenue consists of product revenue, including the distribution in Canada of Klean-Prep and Orthovisc, and royalty payments from Helsinn-Birex... more

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect... more

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated... more

Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. It is developing paclitaxel... more

Therion Biologics Corporation develops therapeutic vaccines that aim to extend and improve the lives of cancer patients. The company has two lead product candidates: PANVAC-VF, entering a Phase III clinical trial for pancreatic cancer; and PROSTVAC® -VF in a Phase II clinical trial for... more

AVAX Technologies, Inc. (AVAX) is a development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. The Company's vaccine consists of autologous (the patient’s own)... more

Intradigm is a private biotechnology company committed to the development of systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of... more

AVEO is committed to developing high value, novel cancer therapeutics which address major unmet medical needs in oncology. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving... more

ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is focused on licensing and... more

Agensys' management team offers in-depth experience in business and science and a track record of significant accomplishment. Donald B. Rice, Ph.D. - Chairman, President and CEO. A founder of Agensys, Dr. Rice was President and COO of Teledyne, Inc. from 1993-1996. He served as... more

ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to discover and develop novel therapeutic approaches for cancer and other diseases. The company's most advanced drug candidate, PNT2258, is expected to advance toward clinical trials in... more

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is... more

AmpliMed® Corporation is a University of Arizona-based, Arizona Board of Regents-approved pharmaceutical company, located in Tucson, Arizona. It was founded in 1989 with the support of The University of Arizona Technology Development Corporation to discover, develop and commercialize... more

Founded in 2000, Sagres Discovery is a biotech company that concentrates on the development of therapeutics in the oncology field. Earlier this year it acquired San Diego-based MemRx Corp. Last winter Sagres arranged significant financial and research support from a large German... more

U3 Pharma AG is an emerging leader in targeted cancer drug development. The company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Prof. Axel Ullrich. U3 Pharma´s vision is to provide clinical oncologists with an... more